title: Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
abstract: BACKGROUND
  Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently used to achieve glycemic targets in patients with type 2 diabetes mellitus (T2DM). The addition of DPP-4 inhibitors to ongoing insulin therapy is expected to reduce insulin dosage, leading to a reduction in the frequency of hypoglycaemia and/or weight gain. Recent studies have demonstrated potential anti-atherosclerotic effects for DPP-4 inhibitors. The aim of the present ongoing study is to assess the effects of sitagliptin on the progression of atherosclerosis in patients with insulin-treated T2DM using carotid intima-media thickness (IMT), an established marker of cardiovascular disease.
  
  
  METHODS
  The Sitagliptin Preventive study of Intima media thickness Evaluation (SPIKE) is a prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study. Between February 2012 and September 2012, 282 participants who failed to achieve glycemic control despite insulin therapy were recruited at 12 clinics and randomly allocated to the sitagliptin group (n = 142) or the control group (n = 140). Primary outcomes are changes in maximum and mean IMT of the common carotid artery after 24-month treatment period measured by carotid arterial echography. Secondary outcomes include changes in glycemic control, parameters related to beta-cell function and diabetic nephropathy, occurrence of cardiovascular events and adverse events such as hypoglycaemia, and biochemical markers of vascular function.
  
  
  CONCLUSIONS
  The present study is designed to assess the effects of sitagliptin on the progression of carotid IMT. Results will be available in the near future, and the findings are expected to provide new strategy to prevent atherosclerosis in patients with insulin-treated T2DM.
  
  
  BACKGROUND
  UMIN000007396.
authors.affiliation: Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. tom-m@juntendo.ac.jp.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Mita
authors.forename: Naoto
authors.initials: N
authors.lastname: Katakami
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Shiraiwa
authors.forename: Hidenori
authors.initials: H
authors.lastname: Yoshii
authors.forename: Tomio
authors.initials: T
authors.lastname: Onuma
authors.forename: Nobuichi
authors.initials: N
authors.lastname: Kuribayashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Osonoi
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kosugi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Umayahara
authors.forename: Tsunehiko
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Kazunari
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Mamiko
authors.initials: M
authors.lastname: Tsugawa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Gosho
authors.forename: Iichiro
authors.initials: I
authors.lastname: Shimomura
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada